- Home
- FOA vs TLSA Comparison
FOA vs TLSA Comparison
Compare FOA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOA | TLSA |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United Kingdom |
| Employees | 747 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.4M | 155.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | FOA | TLSA |
|---|---|---|
| Price | $17.66 | $1.33 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $29.75 | N/A |
| AVG Volume (30 Days) | 99.7K | ★ 111.1K |
| Earning Date | 03-10-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $0.73 |
| 52 Week High | $29.58 | $2.60 |
Technical Indicators
Market Signals| Indicator | FOA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 47.74 |
| Support Level | $16.09 | $1.28 |
| Resistance Level | $23.57 | $1.56 |
| Average True Range (ATR) | 1.13 | 0.09 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 41.42 | 44.64 |
Price Performance
Historical ComparisonAbout FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.